EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

β-(1→3)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: a randomized controlled study

Timothy Erb, Sidonia Mihai, Richard Strauß, Larissa Herbst, Ixchel Castellanos, Katharina Diesch, Franziska Cipa, Karl Bihlmaier, Anne-Katharina Lang, Marion Ganslmayer, Carsten Willam, Frank Bremer und 5 weitere

Antimicrobial Agents and Chemotherapy · 15.11.2023 · 67 (11)

DOI: 10.1128/aac.00725-23 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 15.11.2023. Verfasst von Timothy Erb und 16 weiteren Autor:innen. Beteiligte Einrichtung: Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene; Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU…. Hauptthemen laut MEDLINE: beta-Glucans, Candidiasis, Invasive. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Candida spp. are frequently encountered in specimens from ICUs. However, most of these detections represent colonization. Nevertheless, clinical practice shows that a considerable proportion of these patients will receive antifungal therapy (AT). β-(1→3)-D-glucan (BDG) and mannan are fungal biomarkers with high negative predictive values. We aimed to examine whether biomarker-guided discontinuation of AT can reduce the antifungal consumption. Therefore, we conducted a prospective, randomized intervention study between 1 April 2019 and 31 March 2020. All adult ICU patients with a newly started systemic AT but without fungal infection were eligible for inclusion. Enrolled patients were randomized into an intervention and a control group. In both groups, serum BDG and mannan were determined on days 1 and 2 of AT. If all measurements were negative, AT was discontinued in the intervention group. The primary endpoint was antifungal use. The study was terminated after 12 months. Until this time-point, 41 patients had been included. In the intervention group ( n = 19), AT was stopped in only two patients because all others showed either positive BDG and/or mannan levels. One of these two patients developed candidemia and AT had to be restarted. There was no significant difference in the primary and secondary endpoints. In summary, the strategy of using two negative BDG and mannan levels to stop AT failed to reduce antifungal consumption in our cohort. Indeed, there will inevitably be patients with invasive candidiasis in whom necessary AT is discontinued. The optimal patient population, biomarker set, and termination criteria are critical to the success of biomarker-based termination strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-GlucansCandidiasis, InvasiveAdultHumansAntifungal AgentsMannansGlucansProspective StudiesIntensive Care UnitsBiomarkers

Stichwörter der Autor:innen

Candida infectionantibiotic stewardshipantifungal therapybiomarkercandidemiacandidosisdiscontinuationfungal infection

Substanzen

Antifungal AgentsMannansGlucansbeta-GlucansBiomarkers

Autor:innen und Institutionen

  • Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene; Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg , Erlangen, Germany.
  • Zentrallabor, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg , Erlangen, Germany.
  • Medizinische Klinik 1, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg , Erlangen, Germany.
  • Medizinische Klinik 4, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg , Erlangen, Germany.
  • Anästhesiologische Klinik, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg , Erlangen, Germany.
  • Medizinisches Zentrum für Informations- und Kommunikationstechnik, Universitätsklinikum Erlangen und Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg , Erlangen, Germany.

ORCID-Profile: Jürgen Held

Förderung

  • Deutsche Forschungsgemeinschaft (DFG)

Zitieren

APA

Erb, T., Mihai, S., Strauß, R., Herbst, L., Castellanos, I., Diesch, K., Cipa, F., Bihlmaier, K., Lang, A. K., Ganslmayer, M., Willam, C., Bremer, F., Fürst, J., Beyer, C., Bogdan, C., Rath, A., & Held, J. (2023). β-(1→3)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: a randomized controlled study. Antimicrobial Agents and Chemotherapy, 67(11). https://doi.org/10.1128/aac.00725-23

Vancouver

Erb T, Mihai S, Strauß R, Herbst L, Castellanos I, Diesch K, et al. β-(1→3)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: a randomized controlled study. Antimicrobial Agents and Chemotherapy. 2023;67(11). doi:10.1128/aac.00725-23

BibTeX
@article{Erb2023,
  author = {Erb, Timothy and Mihai, Sidonia and Strauß, Richard and Herbst, Larissa and Castellanos, Ixchel and Diesch, Katharina and Cipa, Franziska and Bihlmaier, Karl and Lang, Anne-Katharina and Ganslmayer, Marion and Willam, Carsten and Bremer, Frank and Fürst, Julia and Beyer, Christian and Bogdan, Christian and Rath, Anca and Held, Jürgen},
  title = {β-(1→3)-D-glucan- and mannan-guided early termination of antifungal therapy in ICU patients: a randomized controlled study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {11},
  doi = {10.1128/aac.00725-23}
}
Kostenlos starten →